Showing posts with label non-inferiority. Show all posts
Showing posts with label non-inferiority. Show all posts
Thursday, September 8, 2016

Hiding the Evidence in Plain Sight: One-sided Confidence Intervals and Noninferiority Trials

›
In the last post, I linked a video podcast of my explaining non-inferiority trials and their inherent biases.  In this videocast, I revisit...
3 comments:
Saturday, June 11, 2016

Non-inferiority Trials Are Inherently Biased: Here's Why

›
Debut VideoCast for the Medical Evidence Blog, explaining non-inferiority trial design and exposing its inherent biases: In this relate...
Monday, May 20, 2013

It All Hinges on the Premises: Prophylactic Platelet Transfusion in Hematologic Malignancy

›
A quick update before I proceed with the current post:   The Institute of Medicine has met and they agree with me that sodium restricti...
1 comment:
Friday, April 19, 2013

David versus Goliath on the Battlefield of Non-inferiority: Strangeness is in the Eye of the Beholder

›
In this week's JAMA is my letter to the editor about the CONSORT statement revision for the reporting of non-inferiority trials, and...
Monday, September 21, 2009

The unreliable assymmetric design of the RE-LY trial of Dabigatran: Heads I win, tails you lose

›
I'm growing weary of this. I hope it stops. We can adapt the diagram of non-inferiority shenanigans from the Gefitinib trial (see http:/...
8 comments:
Tuesday, September 15, 2009

Plavix (clopidogrel), step aside, and prasugrel (Effient), watch your back: Ticagrelor proves that some "me-too" drugs are truly superior

›
Another breakthrough is reported in last week's NEJM: http://content.nejm.org/cgi/content/abstract/361/11/1045 . Wallentin et al report...
4 comments:
Sunday, September 6, 2009

There's no such thing as a free lunch - unless you're running a non-inferiority trial. Gefitinib for pulmonary adenocarcinoma

›
A 20% difference in some outcome is either clinically relevant, or it is not. If A is worse than B by 19% and that's NOT clinically rele...
3 comments:
Tuesday, March 10, 2009

PCI versus CABG - Superiority is in the heart of the angina sufferer

›
In the current issue of the NEJM, Serruys et al describe the results of a multicenter RCT comparing PCI with CABG for severe coronary artery...
5 comments:
Saturday, September 15, 2007

Idraparinux, the van Gogh investigators, and clinical trials pointillism: connecting the dots shows that Idraparinux increases the risk of death

›
It eludes me why the NEJM continues to publish specious, industry-sponsored, negative, non-inferiority trials. Perhaps they do it for my ent...